Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3911 - Pembrolizumab (PEM) in patients with advanced/metastatic bone sarcoma (BS) or soft tissue sarcoma (STS): named patient use by the Medical University of Vienna


11 Sep 2017


Poster display session


Immunotherapy;  Bone Sarcomas;  Soft Tissue Sarcomas


Sophie Schur


Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387


S. Schur1, T. Brodowicz1, B. Gad1, R. Hamacher1, G. Amann2, S. Lang2

Author affiliations

  • 1 Clinical Division Of Oncology, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 2 Department Of Pathology, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT


Abstract 3911


Treatment options in locally advanced/metastatic BS and STS are limited. PEM has shown first signs of promising activity in some histologic subtypes. In this named patient use BS and STS patients who either failed standard therapy or where no standard therapy was established were treated with PEM.


This retrospective analysis includes efficacy/safety data from 18 pts. with advanced/metastatic BS/STS treated with PEM 200mg d1, q21d between May 2016 and April 2017.


10 pts. were female (56%), 8 pts. male (44%). Median age was 45 yrs. (range 18-84 yrs.). Extent of disease at initial diagnosis was localized in 15 pts. (83%) and advanced/metastatic in 3 pts. (17%). The median number of previous lines of systemic treatment before PEM was 3 (range 0-7 lines). In total, 71 cycles of PEM were administered (median 3 cycles per pt., range 1-11 cycles). Immune-related side effects were hypothyroidism in two pts. and uveitis in one pt. PD-L1 assessment on tumor samples is ongoing.Table:


patient IDhistologyn PEM cyclesstatusstatus PEM
1fibromyxoid sarcoma4*1
2OSA1100 NED
4myxofibrosarcoma800 PR
7dedifferentiated LPS700 PR
10chondrosarcoma500 SD
11myxoid LPS300 PR
13dedifferentiated LPS500 SD
14synovialsarcoma300 SD
15epitheloid sarcoma300 PR
16OSA200 ie
17OSA300 ie
18myxoid LPS200 ie

Abbreviation: OSA = osteosarcoma, EMC = extraskeletal myxoid chondrosarcoma, LPS = liposarcoma, status 0 = alive, * = dead; status PEM 0 = PEM ongoing, 1 = PEM discontinued to PD (progressive disease); NED = no evidence of disease, PR = partial remission, SD = stable disease, ie = response in evaluation.


In this unselected cohort, PEM seems to have some activity in advanced/metastatic BS/STS. However, longer follow up of treated patients and prospective clinical trials of PEM in BS/STS patients will define the value of PEM in this patient cohort. Updated efficacy and toxicity data as well as PD-L1 expression levels will be presented at the meeting.

Clinical trial identification

Legal entity responsible for the study

Thomas Brodowicz, Clinical Division of Oncology, Medical University of Vienna




S. Schur: Personal fees from Eli Lilly (advisory board) outside the submitted work. T. Brodowicz: Personal fees from Roche and PharmaMar for lecture fees and from Amgen, Bayer, Novartis, Eisai and Eli Lilly for lecture fees and advisory boards. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.